학술대회 안내 사전등록 안내 초록등록 안내 초록등록/관리 숙박및교통 안내


мȸ ǥ ʷ

ǥ : ȣ - 490037   11 
Combinational Use of Rosuvastatin with Eprosartan or Ramipril Enhances Inhibition of Monocyte Chemoattractant Protein, Interleukin-6, and Cyclooxygenase-2 in Endothelial Cells
전남대학교병원 순환기내과
홍문화, 안영근, 김용숙, 주수연, 김계훈, 손일석, 박형욱, 홍영준, 김주한, 김원, 정명호, 조정관, 박종춘, 강정채
Background: Statin, 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor, is widely used lipid-lowering agent with pleiotropic effect. Angiotensin II receptor blocker (ARB) and angiotensin converting enzyme inhibitor (ACE-I) are used to control hypertension. This study was designed to demonstrate the additional anti-inflammation effects of ARB (eprosartan) or/and ACE-I (ramipril) on use of statin (rosuvastatin). Methods: Rosuvastatin, eprosartan, and ramipril were pretreated in combinations before human umbilical vein endothelial cells (HUVEC) were stimulated by TNF-α (10 ng/mL). Cyclooxygenase (COX)-2, vascular cell adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1, monocyte chemoattractant protein (MCP)-1, interleukin (IL)-6, and IL-8 were analyzed by RT-PCR, western blot, or ELISA. Results: TNF-α increased VCAM-1, ICAM-1, MCP-1, IL-6, and IL-8 expressions at transcription and translation level. Pretreatment of rosuvastatin inhibited mRNA of ICAM-1, MCP-1, IL-8, and COX-2, and proteins of ICAM-1, IL-6, IL-8, and COX-2 in dose-dependent manners. Pretreatment of eprosartan or ramipril also inhibited MCP-1, IL-6, and COX-2 in protein expressions in dose-dependent manners. The expression of MCP-1 was reduced as follows; rosuvastain+eprosartan+ramipril (29.5% of control), rosuvastatin+ramipril (33.0% of control), and rosuvastatin+eprosartan (60.0% of control). The inhibition of IL-6 was redcued as follows; rosuvastain+eprosartan+ramipril (19.9% of control), rosuvastatin+eprosartan (37% of control), and rosuvastatin+ramipril (49.4% of control). Furthermore, COX-2 protein was suppressed in order as follows; rosuvastain+eprosartan+ramipril (8.7% of control), rosuvastatin+eprosartan (11.2% of control), and rosuvastatin+ramipril (29.8% of control). Conclusions: The additional treatment of eprosartan or/and ramipril on rosuvastatin reduced the MCP-1, IL-6, and COX-2 in additive manners. The combination of both eprosartan and ramipril with rosuvastatin attenuates TNF-α induced acute inflammatory process most.


[ư]